Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2004

View Archived Issues

Lovastatin reduces expression of ER-alpha in human breast cancer cell lines

Synergistic action of rosiglitazone and gemcitabine observed in pancreatic cancer cell lines

Novel antinociceptive effects and pharmacokinetics reported for SCIO-469, a p38 MAPK inhibitor

New antibacterial oxazolidinones prepared and tested at Pfizer

New antitumor lamellarin analogues developed at PharmaMar

Predix presents new NK1 antagonists for asthma, pain, emesis, etc.

Novel DPP-IV inhibitors under study at Takeda

Novel progesterone receptor modulators and their use in contraception and gynecological disorders

New mGluR5 antagonists discovered by AstraZeneca and NPS team

Positive results from phase III indiplon trials

Follistim-AQ receives FDA approval

Loss of allergen sensitization reported in children between two and four years of age

New data on the use of epinephrine in the treatment of allergies

Prevention of HBV reactivation during chemotherapy in breast cancer patients

A HER-2 protein vaccine shows promise in breast cancer immunotherapy

BMS-068645 enters phase II trials

Orphan drug designation for pirfenidone for IPF

Active Biotech TTS candidate drug shows promise in pancreatic cancer

Pivotal study for PW-2102 meets primary endpoint

Shire to develop extended release formulations of Q-8003

Enrollment completed in phase IIIb Xyrem study

Inspra approved in Netherlands

Enhance Biotech selects Covance to test LI-313 compound in clinic

Aventis submits new U.S. and E.U. regulatory submissions for Taxotere

Enhanced efficacy of chemotherapy when used with OncoVEX in tumor models

European CPMP recommends approval of Erbitux in colorectal cancer

Merck to discontinue development of EMR-62203

SGN-40 enters phase I trial for multiple myeloma

German consortium to develop TB vaccine

Novel retinoid-related ligand presented by Allergan at AACR meeting

Antitumor activity of JNJ-7706621, an orally available CDK inhibitor, demonstrated in vivo

Final results of the ACTION I study for pimagedine in diabetic nephropathy

Patient exposure and response to pregabalin in GAD

Novel PDE5 inhibitor for erectile dysfunction by Schering Plough